RETRACTED ARTICLE:Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy

Tumor Biology

Volumn 36, Issue 3, 2014, Pages 1589-1594

  Huang, Jinming ^a   Jia, Jiaoyuan ^b   Tong, Qiang ^a   Liu, Jun ^a   Qiu, Jun ^a   Sun, Rong ^a   Yao, Lixin ^a   Yang, Chun ^c  

^a No 85 Hospital of PLA   (China)

^b JILIN UNIVERSITY   (China)

^c WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

Cabazitaxel; Cancerous inhibitor of protein phosphatase 2A; Chemoresistance; Proliferation; Prostate cancer; Small interfering RNA

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; CABAZITAXEL; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN KINASE B; TAXOID;

APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HUMAN; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MEMBRANE PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; TAXOIDS;

EID: 84930905333     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2748-5     Document Type: TB

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.
2. Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–3.
3. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9–12.
4. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014;6(4):167–79.
5. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer. Curr Opin Oncol. 2010;22:263–7.
6. Tannock I, De Wit R, Berry W, Horti J, Pluzanska A, Chi K, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
7. Singh P, Yam M, Russell PJ, Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett. 2010;293:1–14.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54.
9. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12–23.
10. Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res. 2014;20(12):3057–63.
11. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010;29:6257–66.
12. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett. 2011;585:755–60.
13. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54(10):2577–81.
14. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene. 2007;26(35):5070–7.
15. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55(5):300–18. quiz 305-323.
16. Qu YY, Dai B, Kong YY, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl. 2013;15(1):110–5.
17. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.
18. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29(27):3686–94.
19. Keizman D, Maimon N, Gottfried M. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol. 2012;37(3):289–96.
20. Kao SC, Hovey E, Marx G. Second-line therapy for castrate-resistant prostate cancer: a literature review. Asia Pac J Clin Oncol. 2011;7(3):212–23.
21. Lheureux S, Joly F. Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer. 2012;99(9):875–80.
22. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.
23. Zhang S, Wang Y, Chen Z, Kim S, Iqbal S, Chi A, et al. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate. 2013;73(15):1681–9.